YMAB
Y-mAbs Therapeutics, Inc.
Set alert
- Open
- 8.61
- Prev close
- 8.61
- Mkt cap
- 363.24M
- Vol
- 760.67K
- Avg vol
- 249.12K
- EPS
- -0.54
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.61
- High
- 8.61
- Forward P/E
- -13.98
- Beta
- 0.67
- Short ratio
- 13.91
- Inst. own
- 72.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 12.41
- 200-d avg
- 13.15
- 1y target
- 20.64
Key statistics
- Market cap
- 363.24M
- Enterprise value
- 303.81M
- Trailing P/E
- 0.00
- Forward P/E
- -13.98
- PEG ratio
- 0.00
- Price / sales
- 4.30
- Price / book
- 3.93
- EPS (TTM)
- -0.54
- Beta
- 0.67
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -28.22%
- Revenue (TTM)
- 84.55M
- Revenue growth
- -9.70%
- Free cash flow
- 1.19M
- Total cash
- 68.12M
- Total debt
- 1.07M
- Return on equity
- -24.78%
- Shares outstanding
- 44.79M
- Short % of float
- 10.28%
- 50-day average
- 12.41
- 200-day average
- 13.15
Analyst view
Consensus: buy
- Target (low)
- 11.00
- Target (mean)
- 20.64
- Target (high)
- 26.00
- Strong buy2
- Buy7
- Hold1
- Sell1
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.1225.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.14 | -0.16 | -0.02 | -14.29% |
| Aug 12, 2024 | Jun 1, 2024 | -0.13 | -0.21 | -0.08 | -61.54% |
| Aug 12, 2024 | Jun 1, 2024 | -0.13 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.12 | -0.15 | -0.03 | -25.00% |
| May 7, 2024 | Mar 1, 2024 | -0.12 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.19 | -0.02 | +0.17 | +89.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 5, 2024 | Brookline Capital | init | — | Buy |
| Nov 18, 2024 | Oppenheimer | init | — | Outperform |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 10, 2024 | Wedbush | reit | Outperform | Outperform |
| Sep 9, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
About Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ymabs.com
News
- Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?
- Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
- Deal Dispatch: Performance Food Group And Claire's Lead A Week Of Big Auctions, Retail Woes
- Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
- Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders
- Y-mAbs (YMAB) Q2 Revenue Falls 14%
- Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
- Earnings Scheduled For August 8, 2025
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)
- Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
Your note
Sign in to keep a note on YMAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GAD THOMAS | Officer and Director | Conversion of Exercise of derivative security | Sep 18, 2024 | 309,212 |
| GILL DAVID N. | Director | Stock Award(Grant) | Jun 10, 2024 | 5,825 |
| HAMILL LAURA | Director | Stock Award(Grant) | Jun 10, 2024 | 5,825 |
| HEALY JAMES I | Director | Stock Award(Grant) | Jun 10, 2024 | 2,225,880 |
| LUND-HANSEN TORBEN | Chief Technology Officer | Conversion of Exercise of derivative security | Aug 27, 2024 | 81,262 |
| PFREUNDSCHUH PETER P | Chief Financial Officer | Stock Award(Grant) | Jul 11, 2024 | 46,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 9.12% | 4,086,346 | 33.14M | Sep 29, 2024 |
| Blackrock Inc. | 6.75% | 3,025,235 | 24.53M | Sep 29, 2024 |
| Sofinnova Investments, Inc. | 4.90% | 2,194,278 | 17.80M | Sep 29, 2024 |
| Vanguard Group Inc | 4.54% | 2,035,363 | 16.51M | Sep 29, 2024 |
| Polar Capital Holdings PLC | 4.09% | 1,831,000 | 14.85M | Sep 29, 2024 |
| Cormorant Asset Management, LP | 3.24% | 1,450,000 | 11.76M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.32% | 1,040,061 | 8.43M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.13% | 951,950 | 7.72M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.07% | 478,047 | 3.88M | Sep 29, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 0.90% | 403,188 | 3.27M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.84% | 377,276 | 3.06M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.73% | 327,482 | 2.66M | Oct 30, 2024 |